681161-44-4Relevant articles and documents
Identification of bivalent ligands with melatonin receptor agonist and fatty acid amide hydrolase (FAAH) inhibitory activity that exhibit ocular hypotensive effect in the rabbit
Spadoni, Gilberto,Bedini, Annalida,Furiassi, Lucia,Mari, Michele,Mor, Marco,Scalvini, Laura,Lodola, Alessio,Ghidini, Andrea,Lucini, Valeria,Dugnani, Silvana,Scaglione, Francesco,Piomelli, Daniele,Jung, Kwang-Mook,Supuran, Claudiu T.,Lucarini, Laura,Durante, Mariaconcetta,Sgambellone, Silvia,Masini, Emanuela,Rivara, Silvia
, p. 7902 - 7916 (2018/09/18)
Activation of melatonin receptors and inhibition of fatty acid amide hydrolase (FAAH) have both shown potential benefits for the treatment of glaucoma. To exploit the combination of these biological activities in single therapeutic agents, we designed dua
As opioid receptor antagonists or inverse agonists of the novel compounds
-
Paragraph 0146-0149; 0151, (2016/10/08)
Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
Applying a multitarget rational drug design strategy: The first set of modulators with potent and balanced activity toward dopamine D3 receptor and fatty acid amide hydrolase
De Simone, Alessio,Ruda, Gian Filippo,Albani, Clara,Tarozzo, Glauco,Bandiera, Tiziano,Piomelli, Daniele,Cavalli, Andrea,Bottegoni, Giovanni
supporting information, p. 4904 - 4907 (2014/05/06)
Combining computer-assisted drug design and synthetic efforts, we generated compounds with potent and balanced activities toward both D3 dopamine receptor and fatty acid amide hydrolase (FAAH) enzyme. By concurrently modulating these targets, our compounds hold great potential toward exerting a disease-modifying effect on nicotine addiction and other forms of compulsive behavior.